Cargando…

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns

BACKGROUND: Since direct oral anticoagulants (DOACs) have been introduced for treatment and prevention of thromboembolic diseases, patients on vitamin K antagonists (VKA) have to decide whether to remain on VKA or switch to DOAC. The goal of this study was to evaluate treatment satisfaction, prefere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toorop, Myrthe M. A., van Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., van der Meer, Felix J. M., Cannegieter, Suzanne C., Lijfering, Willem M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318134/ https://www.ncbi.nlm.nih.gov/pubmed/32170987 http://dx.doi.org/10.1111/jth.14793

Ejemplares similares

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda D., et al.
Publicado: (2021)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2022)

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study
por: Toorop, Myrthe M A, et al.
Publicado: (2021)

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients
por: Stals, Milou A. M., et al.
Publicado: (2021)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
por: Orsi, Fernanda A., et al.
Publicado: (2019)

Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study
por: Orsi, Fernanda A., et al.
Publicado: (2021)

Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
por: van Dam, Lisette F., et al.
Publicado: (2021)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower‐leg injury or knee arthroscopy
por: Mohammed, Yassene, et al.
Publicado: (2022)

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists()
por: Visser, Chantal, et al.
Publicado: (2023)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Anticoagulation practice patterns in COVID‐19: A global survey
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
por: Bakker, Sanne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m6per37l15snkme8jrko8dm0ta